One guideline focuses on managing severe asthma and the other begins with recommendations for mild intermittent asthma before increasing based on disease severity, noted Megan Althoff, MD, PhD, University of Colorado.
One guideline focuses on managing severe asthma and the other begins with recommendations for mild intermittent asthma before increasing based on disease severity, noted Megan Althoff, MD, PhD, second-year fellow, University of Colorado, Division of Pulmonary Sciences and Critical Care Medicine.
Transcript
How do the various asthma guidelines differ? What should future guidelines address?
The ERS/ATS [European Respiratory Society/American Thoracic Society] guidelines focus really just on the management of severe asthma, so in that way [they are] different from GINA [Global Initiative for Asthma], which is going to start you with a mild intermittent asthma and works your way up. So ERS/ATS was focused on 6 questions around severe asthma management.
I think one of the biggest differences between the ERS/ATS and GINA is especially with the IL-5 [interleukin-5] and IL-5 receptor antagonists—mepolizumab, reslizumab, and benralizumab—the ERS/ATS guidelines think they're worth trying in patients who have peripheral eosinophils greater than 150, whereas GINA recommends choosing any of those therapies if your patient has a peripheral eosinophil count over 300.
So the patient sitting in front of you who's kind of in between those 2 ranges, GINA would say, if you will, there’s a lower chance this is going to be successful in your patient, whereas when ERS/ATS reviewed the literature, they think there's not enough strong data to suggest that you shouldn't try it in an uncontrolled patient who has slightly lower peripheral eosinophils.
Similarly, with dupilumab, which is the anti–IL-4 receptor alpha subunit antagonist, ERS/ATS recommends trying that in any patient, regardless of their peripheral eosinophil count, if they're uncontrolled on an oral corticosteroid, whereas GINA says to try it if they have greater than 150 eosinophils. So that's practically a pretty big difference.
The other difference was the ERS/ATS guidelines talked about the long-acting antimuscarinics, or tiotropium specifically—that’s the one most thoroughly studied—and they had recommended trying that in patients who are uncontrolled at GINA’s step 4 and 5, whereas GINA recommends considering it more in non-Th2 asthmatics and if you're uncontrolled at step 5.
So ERS/ATS is a little bit more pro starting a LAMA [long-acting muscarinic antagonist] a little bit earlier in therapy and for more patients. Those are kind of the biggest differences, I think, between the 2 guidelines.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More